efficacy of transcatheter arterial chemoembolization alone or combined with microwave ablation in treatment of primary large liver cancer: a comparative analysis
Clicks: 174
ID: 154176
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
174 views
16 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #47 of 78 articles by views in lontar komputer
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveTo retrospectively analyze the short-term efficacy and long-term survival rates of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave coagulation therapy (PMCT) versus TACE monotherapy in the treatment of large primary hepatic carcinoma. MethodsSixty-seven patients with unresectable large primary hepatic carcinoma(＞5.0 cm) who were admitted to our hospital from February 2011 to May 2014 were enrolled as subjects. Among these patients, 34 patients received TACE monotherapy and 33 patients received TACE combined with PMCT. At one month after treatment, the abdomen was re-examined using contrast-enhanced computed tomography or magnetic resonance imaging, and liver function and alpha-fetoprotein (AFP) level were measured. The follow-up period varied from 3 to 36 months. Comparison of short-term outcomes, AFP level, and long-term survival rates were performed between the two groups. Comparison of continuous data was made by t test, and comparison of categorical data by χ2 test and Fisher′s test. ResultsThe complete ablation rate and the response rate were significantly higher in the combination therapy group than in the TACE monotherapy group (54.5% vs 20.6%, P=0.004; 97% vs 64.7%, P=0.001). The AFP level after treatment with combination therapy was significantly lower than that before treatment with combination therapy and that after treatment with TACE monotherapy (P＜0001; P＜0001). Patients in both groups had varying degrees of liver dysfunction and elevated aminotransferase, but with no severe complications such as bleeding, gastrostoma, colon fistula, bile duct injury, and needle tract metastasis, as well as deaths. The median survival time in the combination therapy group and the TACE monotherapy group was 13 months and 9 months, respectively, and the mean survival time was 14.00±1.63 months and 10.83±1.19 months, respectively. The 1-, 2-, and 3-year overall survival rates in the combination therapy group were significantly higher than those in the TACE monotherapy group (63.6% vs 28.4%; 15.2% vs 5.9%; 4.5% vs 0%; P=0044). ConclusionTACE combined with PMCT is a safe and effective therapy regimen, which achieves better treatment outcomes in local tumor control, substantially lower AFP level, and longer survival time than TACE monotherapy.
| Reference Key |
peng2015linchuangefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;CHANG Peng |
| Journal | lontar komputer |
| Year | 2015 |
| DOI |
10.3969/j.issn.1001-5256.2015.06.013
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.